A narrower follow-up, since the general answer is now clear:
How would you tell the difference between that and the alternative explanation?
anders_CPH said:Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…
I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.
anders_CPH said:Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…
Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL Biochemanders_CPH said:Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…
Saving this. It is the first explanation that did not require me to already understand it. Adding it to my notes with a link back to this thread.
Closing the loop on my own question.
The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.